SCLC,Extensive Stage Clinical Trials

13 recruitingLast updated: June 17, 2026

There are 13 actively recruiting sclc,extensive stage clinical trials across 10 countries. Studies span Phase 2, Phase 1. Top locations include Shanghai, China, Beijing, Beijing Municipality, China, Avignon, France. Updated daily from ClinicalTrials.gov.


SCLC,Extensive Stage Trials at a Glance

13 actively recruiting trials for sclc,extensive stage are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Shanghai, Beijing, and Avignon. Lead sponsors running sclc,extensive stage studies include Beijing Biotech, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and Arbeitsgemeinschaft medikamentoese Tumortherapie.

Browse sclc,extensive stage trials by phase

Treatments under study

About SCLC,Extensive Stage Clinical Trials

Looking for clinical trials for SCLC,Extensive Stage? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new SCLC,Extensive Stage trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about SCLC,Extensive Stage clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

SCLC,Extensive StageSLFN11-positive
ETOP IBCSG Partners Foundation44 enrolled18 locationsNCT05718323
Recruiting
Phase 1Phase 2

68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer

SCLCSmall Cell Lung CancerSCLC,Extensive Stage+2 more
Peking University First Hospital30 enrolled1 locationNCT07508852
Recruiting
Phase 1Phase 2

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

SCLC,Extensive StageSmall Cell Lung Cancer ( SCLC )Relapsed/Refractory SCLC
Beijing Biotech60 enrolled1 locationNCT07480213
Recruiting
Phase 2

Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

SCLCSCLC,Extensive Stage
Cancer Institute and Hospital, Chinese Academy of Medical Sciences20 enrolled2 locationsNCT07110103
Recruiting
Phase 1

A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment

SCLC,Extensive Stage
Peking University Cancer Hospital & Institute24 enrolled1 locationNCT07413042
Recruiting
Phase 2

A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors

Advanced Solid TumorsSCLC,Extensive Stage
Shanghai AB PharmaTech Ltd.110 enrolled8 locationsNCT07321574
Recruiting
Phase 2

Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy

SCLC,Extensive Stage
Tang-Du Hospital32 enrolled1 locationNCT07141264
Recruiting
Phase 1Phase 2

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

SCLC,Extensive Stage
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.27 enrolled2 locationsNCT07136285
Recruiting
Phase 2

A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC

SCLC,Extensive Stage
Shanghai Henlius Biotech26 enrolled1 locationNCT06812260
Recruiting
Phase 1

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

SCLC,Extensive Stage
RayzeBio, Inc.49 enrolled15 locationsNCT05595460
Recruiting
Phase 2

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

SCLC,Extensive Stage
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS60 enrolled12 locationsNCT05623319
Recruiting

Lung Cancer Registry

Lung CancerNSCLC Stage IVNSCLC Stage III+2 more
Arbeitsgemeinschaft medikamentoese Tumortherapie500 enrolled3 locationsNCT04654364
Recruiting
Phase 1Phase 2

WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases

Brain MetastasesSCLC,Extensive Stage
Fudan University56 enrolled1 locationNCT06243003